IGF-1 LR3: Long-Acting Growth Factor in Muscle Research

IGF-1 LR3 (Long R3 IGF-1) is a synthetic analogue of human insulin-like growth factor 1 in which an arginine replaces the glutamate at position 3 and a 13-amino-acid extension is added to the N-terminus, giving 83 residues in place of the native 70. Those two changes sharply reduce its affinity for the IGF-binding proteins that normally hold IGF-1 in check, so it stays active in cell culture and animal models for far longer than the native hormone. In the UK it is supplied as a research chemical for laboratory use only and has no MHRA marketing authorisation.

This guide covers where IGF-1 LR3 came from, why it behaves differently from ordinary IGF-1, what the peer-reviewed research actually reports in muscle, gut and cell-culture models, and what UK researchers should look for before buying it.

What is IGF-1 LR3?

Insulin-like growth factor 1 is a 70-amino-acid peptide hormone produced mainly by the liver in response to growth hormone. It is the principal mediator of GH's anabolic effects on muscle, bone and connective tissue. In blood, more than 95% of IGF-1 is carried by a family of six IGF-binding proteins (IGFBP-1 to IGFBP-6), which extend its half-life but also limit how much is free to reach the type 1 IGF receptor at any given moment.

IGF-1 LR3 was engineered in the early 1990s by a group in Adelaide, Australia, working with GroPep and the CSIRO. The design goal was a version of IGF-1 that binding proteins could not sequester. Both modifications sit in the region IGFBPs recognise, so the analogue binds IGFBPs very weakly while keeping most of its affinity for the type 1 IGF receptor. The name is simply descriptive: Long for the N-terminal extension, R3 for the arginine at position 3.

The same molecule is sold under the trade name LONG R3 IGF-I as a cell-culture supplement in biopharmaceutical manufacturing, where it replaces insulin in serum-free media for Chinese hamster ovary (CHO) cells. That industrial use is the reason there is a substantial body of well-characterised data on the compound.

IGF-1 LR3 vs native IGF-1

The founding paper is Francis, Ross, Ballard and colleagues in the Journal of Molecular Endocrinology (1992), which compared several recombinant fusion-protein analogues of IGF-1. The authors concluded that loss of IGFBP binding, rather than any gain in receptor affinity, explained the enhanced biological potency of the long-form analogues. In serum-containing culture medium, where bovine IGFBPs are present, LR3 IGF-1 was roughly two to three times more potent than native IGF-1 on a molar basis; in serum-free medium, where no binding proteins are present, the two were essentially equal.

Supplier marketing often quotes a functional half-life of 20 to 30 hours for IGF-1 LR3 against a few minutes for free IGF-1. The comparison is misleading in both directions: free IGF-1 is cleared within minutes, but IGFBP-bound IGF-1 circulates for many hours, and the widely repeated LR3 figure does not trace back to a clean pharmacokinetic study. What the literature does support is that LR3 remains biologically available because it is not sequestered, not that it is intrinsically more stable.

What the research says about IGF-1 LR3 in muscle and growth

Most of the primary IGF-1 LR3 literature comes from the Adelaide group and dates from the 1990s, when the analogue was being evaluated as a growth-promoting agent in livestock and as a tool for studying IGF biology. Three lines of evidence stand out.

Rat growth and protein metabolism. Tomas, Ballard and colleagues in the Journal of Endocrinology (1993) gave graded doses of IGF-1, des(1-3)IGF-1 and LR3 IGF-1 to normal female rats. The analogues with reduced IGFBP affinity produced greater weight gain and nitrogen retention than native IGF-1 at equivalent doses, and gut weight rose by up to 45%. Related work in dexamethasone-treated rats, a catabolic model, showed that the N-terminally modified analogues restored growth and induced marked intestinal growth. These are the studies behind the description of IGF-1 LR3 as a muscle research peptide, although the gut effect is at least as prominent as the muscle effect.

Pig studies and the feedback loop. Work in growing pigs reported that LR3 IGF-1 infusion reduced plasma growth hormone, IGFBP-3 and endogenous IGF-1 concentrations, and in some designs reduced rather than increased overall growth. This matters for interpretation: because IGF-1 feeds back on the pituitary, an analogue that signals strongly can suppress the animal's own GH-IGF axis. Researchers modelling the GH axis, for example alongside CJC-1295, ipamorelin or tesamorelin, need to account for that.

Satellite cells and myogenesis. IGF-1 is one of the best-characterised activators of muscle satellite cells, the resident stem cells that fuse into fibres during hypertrophy and repair, and it drives the PI3K-Akt-mTOR pathway that increases protein synthesis. Much of this mechanistic work used native IGF-1 or muscle-specific IGF-1 isoforms in cultured myoblasts and transgenic mice; IGF-1 LR3 is used in these assays mainly as a binding-protein-resistant tool that gives a cleaner signal in serum-containing media.

How IGF-1 LR3 is used in the laboratory

The single largest use of IGF-1 LR3 worldwide is not in peptide research at all but in bioprocessing. Because it is not mopped up by the IGFBPs present in culture, it supports CHO cell growth and antibody production at nanomolar concentrations. Repligen reports volumetric productivity gains of up to 62% over unsupplemented culture and around 40% over insulin-supplemented culture. Outside manufacturing, typical research applications include:

• Myoblast proliferation and differentiation assays (C2C12 and primary satellite cells) where a binding-protein-resistant IGF-1 signal is wanted.
• Studies separating IGF receptor signalling from IGFBP effects, using LR3 as the IGFBP-blind comparator to native IGF-1.
• Animal models of catabolic states and gut growth, following the Tomas and Ballard protocols.
• Cell-culture media development and serum-free adaptation.
• Analytical work on IGF-1 detection, since LR3 is structurally distinct and used as a reference in anti-doping method development.

Cautions raised in the literature

IGF-1 signalling is mitogenic and anti-apoptotic, and elevated IGF-1 activity is a recognised risk factor in several cancers, which is why IGF-1 receptor inhibitors have been trialled as oncology drugs. In animal studies IGF-1 and its analogues also lower blood glucose, an insulin-like effect that is the origin of the hormone's name. Any research design involving IGF-1 LR3 has to consider both.

IGF-1 and its analogues are also listed under section S2 of the World Anti-Doping Agency Prohibited List. That is a sporting rule rather than a UK law, but it is one more reason the compound belongs in a laboratory rather than a gym bag.

Is IGF-1 LR3 legal in the UK?

IGF-1 LR3 is legal to buy, sell and possess in the UK as a research chemical. It is not a controlled substance under the Misuse of Drugs Act 1971 and it is not covered by the Psychoactive Substances Act 2016. It has no MHRA marketing authorisation, so supplying it for human medicinal use, or marketing it with medicinal claims, is unlawful under the Human Medicines Regulations 2012. Reputable UK suppliers sell it strictly for research, and this article describes published findings rather than making claims about any product.

What to check before you buy IGF-1 LR3 in the UK

IGF-1 LR3 is a recombinant protein, not a short synthetic peptide, which changes what quality means. It is produced by expression in E. coli or yeast and then folded and purified, so identity, purity and correct folding all matter. Misfolded or aggregated material can look pure on a crude assay while being biologically inert.

1. Ask for a batch-specific certificate of analysis showing HPLC purity and mass-spectrometry identity. Calibre pens are tested by Janoshik Analytical and COAs are published on the site's COA page.
2. Check the stated quantity is the protein content, not the gross weight including excipients. Calibre's IGF-1 LR3 pen is a 1mg pen, which is a typical research quantity for a compound active at nanomolar concentrations.
3. Look for a purity target above 99% and a clear statement of the expression system if you need it for your methods section.
4. Store as directed: recombinant proteins are more sensitive to freeze-thaw cycles and agitation than short peptides.
5. Prefer pre-filled, precision-made pens if your workflow benefits from consistent volumes without reconstituting lyophilised powder.

Summary

IGF-1 LR3 is one of the more thoroughly characterised research peptides because of its industrial history: the mechanism is clear, the in vitro potency data are robust and the 1990s animal work is real, if narrow and largely from a single group. What it lacks entirely is human trial evidence. For UK researchers it is legal to buy as a research chemical, and the important checks are the same as for any recombinant protein: batch-specific COA, confirmed identity, and careful storage.